Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Trial shows epoetin alfa use to maintain Hb resulted in decreased survival
October 20th, 2005
Recent breast cancer trial results show that epoetin alfa used to maintain Hb targets resulted in decreased survival and quality of life. In a report published in the Journal of Clinical Oncology, researchers in Canada conducted a study "To evaluate the effect on survival and quality of life of maintaining hemoglobin (Hb) in the range of 12 to 14 g/dL with epoetin alfa versus placebo in women with metastatic breast cancer (MBC) receiving first-line chemotherapy. Eligible patients were randomly assigned to receive epoetin alfa 40,000 U once weekly or placebo for 12 months. Study drug was initiated if baseline Hb was {{<=}}13 g/dL or when Hb decreased to...
Source: Women's Health Weekly (2005-10-20)
|
